Omar Mamlouk

30 posts

Omar Mamlouk

Omar Mamlouk

@onconephron

Onco-nephrologist at The University of Texas MD Anderson Cancer Center

Houston, TX Katılım Ocak 2014
60 Takip Edilen67 Takipçiler
Omar Mamlouk retweetledi
Harish Seethapathy
Harish Seethapathy@BetterCallSeeth·
🚨 Rapid vs standard taper for immune checkpoint inhibitor #AIN. Tweetorial on our study which is out on @jitcancer #onconephrology @MegSise @MGHKidneys @MGHCancerCenter
Journal for ImmunoTherapy of Cancer@jitcancer

New #JITC article: Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study @BetterCallSeeth ow.ly/Qs8T50Epj5l

English
1
9
28
0
Omar Mamlouk retweetledi
Nature Reviews Nephrology
Nature Reviews Nephrology@NatRevNeph·
New Review online! Kidney injury and disease in patients with haematological malignancies, including injury caused by monoclonal gammopathies, tumour and paraneoplastic disorders, and anti-cancer treatment. go.nature.com/3m6Imdy #onconephrology
Nature Reviews Nephrology tweet media
English
0
38
95
0
Omar Mamlouk retweetledi
JASN_News
JASN_News@JASN_News·
In this pilot study of patients with proliferative GN with monoclonal immunoglobulin deposition, the monoclonal anti-CD38 antibody daratumumab exhibited an acceptable safety profile and improvement in proteinuria while stabilizing kidney function bit.ly/j2020101541
JASN_News tweet media
English
0
25
41
0
Omar Mamlouk retweetledi
JASN_News
JASN_News@JASN_News·
A study of a large cohort of adult survivors of childhood cancer found that 2.1% had stage 3–5 CKD, which was associated with treatment ever with a calcineurin inhibitor, cumulative dose of some chemotherapy agents, kidney irradiation, and other factors bit.ly/j2020060849
English
0
1
4
0
Omar Mamlouk retweetledi
KIReports
KIReports@KIReports·
Diagnostic approach to glomerulonephritis with fibrillar IgG deposits and light chain restriction doi.org/10.1016/j.ekir…
KIReports tweet media
English
0
16
26
0
Omar Mamlouk retweetledi
Abhijat Kitchlu | Onconephrology
An individualized approach, with collaboration between oncologists, urologists and nephrologists is needed for many patients with CKD who may be candidates for cisplatin treatment #onconephrology @NephroGuy
Maria Jiang@DiMariaJiang

CrCl<60 should not automatically exclude MIBC pts from cisplatin-based NAC. Need multiD and pt-centered approach to minimize undertreatment. Our take on cis-eligibility criteria for MIBC: pubmed.ncbi.nlm.nih.gov/33432181/ @shilpaonc @onconeph @NormandBlais @Nimira_A @Uromigos @UHN

Toronto, Ontario 🇨🇦 English
1
3
16
0